30 results
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
12 Mar 24
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
4:06pm
and ASO programs in 2022, partially offset by increases in our ongoing activities and related expenditures associated with our CAM clinical trial … and patent attorney costs, partially offset by a decrease in facility expenses. Total G&A stock-based compensation expense incurred for the year ended
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
2 Nov 23
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
4:05pm
-related costs and other costs including facility expenses, partially offset by an increase in third party expenses due to the milestone payments made
8-K
EX-99.1
sg2zuu0fq ji8s32c9n
3 Aug 23
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
x7oyg6n
4 May 23
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
f7y4tub1t jy
4 Aug 22
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
qf4jgbyy7q7
4 May 22
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results
4:06pm
424B4
20cp2bqrjo
1 Jul 21
Prospectus supplement with pricing info
4:31pm
DRS
v3opdu4lrf
4 Jun 21
Draft registration statement
12:00am